These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23296585)

  • 1. Don't tamper with oxycodone.
    Fletcher J; Tsuyuki R
    CMAJ; 2013 Feb; 185(2):107. PubMed ID: 23296585
    [No Abstract]   [Full Text] [Related]  

  • 2. Trends and uptake of new formulations of controlled-release oxycodone in Canada.
    Gomes T; Jain S; Paterson JM; Sketris I; Caetano P; Henry D;
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):520-525. PubMed ID: 29359446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who's writing the script?
    Miller A
    CMAJ; 2013 Feb; 185(2):114-5. PubMed ID: 23251017
    [No Abstract]   [Full Text] [Related]  

  • 4. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technology: Barriers to misuse.
    Dolgin E
    Nature; 2015 Jun; 522(7557):S60-1. PubMed ID: 26107099
    [No Abstract]   [Full Text] [Related]  

  • 6. Abuse deterrence focus of upcoming opioid formulations.
    Lavine G
    Am J Health Syst Pharm; 2008 Mar; 65(5):381, 385. PubMed ID: 18281726
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
    Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
    Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
    Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid use following the introduction of an extended-release oxycodone formulation with tamper-resistant properties: Prospective historical chart review in methadone-maintained patients.
    Sankey C; Setnik B; Harsanyi Z; Michalko K; Yang Z; Geoffroy P
    J Opioid Manag; 2016; 12(2):149-59. PubMed ID: 27194200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid rain: opioid prescribing is growing and practice is diverging.
    Davis A; Davis K; Gerard C; Goyal S; Jackson G; James C; Loe E; Nicolls B; O'Rourke MA; Shuker C; Te Karu L
    N Z Med J; 2016 Aug; 129(1440):11-7. PubMed ID: 27538034
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.
    Schaffer AL; Buckley NA; Degenhardt L; Larance B; Cairns R; Dobbins TA; Pearson SA
    CMAJ; 2018 Mar; 190(12):E355-E362. PubMed ID: 29581162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Formulation Advances in Extended-Release Medications for Pain Control.
    Jones MR; Carney MJ; Kaye RJ; Prabhakar A; Kaye AD
    Curr Pain Headache Rep; 2016 Jun; 20(6):36. PubMed ID: 27084375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
    Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
    Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons.
    Jauncey M; Livingston M; Salmon AM; Dietze P
    Int J Drug Policy; 2018 Mar; 53():17-22. PubMed ID: 29268238
    [No Abstract]   [Full Text] [Related]  

  • 17. Don't overlook directions.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Dec; 96(12):14-5. PubMed ID: 8961854
    [No Abstract]   [Full Text] [Related]  

  • 18. Aglukkaq asks for US help to control oxycodone.
    Miller A
    CMAJ; 2013 May; 185(8):E317-8. PubMed ID: 23569162
    [No Abstract]   [Full Text] [Related]  

  • 19. Opioid Use and Overdose: What We've Learned in Ontario.
    Gomes T; Juurlink DN
    Healthc Q; 2016; 18(4):8-11. PubMed ID: 27009700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?
    Raffa RB; Taylor R; Pergolizzi JV
    Expert Opin Drug Saf; 2014 Feb; 13(2):181-90. PubMed ID: 24206269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.